TEVA's pathfinder tour of DPP-Ⅳ inhibitor generic drugs
WU Bin
DENG Sheng-ju
MIAO Yan-ni
Abstract：DPP-Ⅳ inhibitors are very important drugs in the treatment of diabetes,and the market is highly competitive.In this review,information about global patent distribution,EPO opposition-appeal process,abbreviated new drug application (ANDA) and the US patent litigation of TEVA pharmaceuticals in DPP-Ⅳ inhibitors,were searched,and the market-oriented strategy of TEVA on the DPP-Ⅳ inhibitors were comprehensively analyzed,which will provide references for Chinese generic drug companies.
Keywords：DPP-ⅣTEVA pharmaceuticalsgeneric drugspatentlitigationabbreviated new drug application (ANDA)opposition
Publication Date：2017-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：4( 1985-1988 )